KRAS and cancer: The cell viability assays showed that cancer cell lines (MIA PaCa-2, CFPAC-1, Capan-1, and SW1990) harboring KRas mutations displayed a striking inhibition of cell survival in a dose-dependent manner (Figure 2A).